Therapeutic compositions and uses of alpha1-antitrypsin: a patent review (2012 – 2015)

References

• Laurell CB, Eriksson S. The electrophoretic alpha1-globulin pattern of serum in alpha1-antitrypsin deficiency. 1963. Copd. 2013;10(Suppl 1):3–8.
   PubMedGoogle Scholar
• Cowden DI, Fisher GE, Weeks RL. A pilot study comparing the purity, functionality and isoform composition of alpha-1-proteinase inhibitor (human) products. Curr Med Res Opin. 2005;21:877–883.
   PubMed Web of Science ®Google Scholar
• Silverman EK, Sandhaus RA. Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med. 2009;360:2749–2757.
   PubMed Web of Science ®Google Scholar
• Teschler H. Long-term experience in the treatment of alpha1-antitrypsin deficiency: 25 years of augmentation therapy. Eur Respir Rev. 2015;24:46–51.
   PubMed Web of Science ®Google Scholar
• Hubbard RC, Crystal RG. Augmentation therapy of alpha 1-antitrypsin deficiency. Eur Respir J Suppl. 1990;9:44s–52s.
   PubMedGoogle Scholar
• Brinkman EC, Hack CE, Van Den Nieuwenhof I, Recombinant human alpha1-antitrypsin. US20120214747A1. 2013.
   Google Scholar
• Gadek JE, Klein HG, Holland PV, et al. Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest. 1981;68:1158–1165.
   PubMed Web of Science ®Google Scholar
• Cohn EJ, Strong LE, et al. Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc. 1946;68:459–475.
   PubMed Web of Science ®Google Scholar
• Janciauskiene S, Eriksson S. In vitro complex formation between cholesterol and alpha 1-proteinase inhibitor. FEBS Lett. 1993;316:269–272.
   PubMed Web of Science ®Google Scholar
• Karlsson H, Leanderson P, Tagesson C, et al. Lipoproteomics II: mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics. 2005;5:1431–1445.
   PubMed Web of Science ®Google Scholar
• Kolarich D, Turecek PL, Weber A, et al. Biochemical, molecular characterization, and glycoproteomic analyses of alpha(1)-proteinase inhibitor products used for replacement therapy. Transfusion. 2006;46:1959–1977.
   PubMed Web of Science ®Google Scholar
• Alkins SA, O’Malley P. Should health-care systems pay for replacement therapy in patients with alpha(1)-antitrypsin deficiency? A critical review and cost-effectiveness analysis. Chest. 2000;117:875–880.
   PubMed Web of Science ®Google Scholar
• Hosokawa N, Tremblay LO, You Z, et al. Enhancement of endoplasmic reticulum (ER) degradation of misfolded Null Hong Kong alpha1-antitrypsin by human ER mannosidase I. J Biol Chem. 2003;278:26287–26294.
   PubMed Web of Science ®Google Scholar
• Wu Y, Swulius MT, Moremen KW, et al. Elucidation of the molecular logic by which misfolded alpha 1-antitrypsin is preferentially selected for degradation. Proc Natl Acad Sci U S A. 2003;100(p):8229–8234.
   PubMed Web of Science ®Google Scholar
• Kwon KS, Yu MH. Effect of glycosylation on the stability of alpha1-antitrypsin toward urea denaturation and thermal deactivation. Biochim Biophys Acta. 1997;1335:265–272.
   PubMed Web of Science ®Google Scholar
• Casolaro MA, Fells G, Wewers M, et al. Augmentation of lung antineutrophil elastase capacity with recombinant human alpha-1-antitrypsin. J Appl Physiol (1985). 1987;63:2015–2023.
   PubMed Web of Science ®Google Scholar
• Stockley RA. The multiple facets of alpha-1-antitrypsin. Ann Transl Med. 2015;3:130.
   PubMed Web of Science ®Google Scholar
• Ozeri E, Mizrahi M, Shahaf G, et al. alpha-1 antitrypsin promotes semimature, IL-10-producing and readily migrating tolerogenic dendritic cells. J Immunol. 2012;189:146–153.
   PubMed Web of Science ®Google Scholar
• Pott GB, Chan ED, Dinarello CA, et al. Alpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. J Leukoc Biol. 2009;85:886–895.
   PubMed Web of Science ®Google Scholar
• Tilg H, Vannier E, Vachino G, et al. Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells. J Exp Med. 1993;178:1629–1636.
   PubMed Web of Science ®Google Scholar
• Martin SL, Downey D, Bilton D, et al. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol. 2006;41:177–183.
   PubMed Web of Science ®Google Scholar
• Bergin DA, Reeves EP, Meleady P, et al. alpha-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J Clin Invest. 2010;120:4236–4250.
   PubMed Web of Science ®Google Scholar
• Finotti P, Pagetta A. A heat shock protein70 fusion protein with alpha1-antitrypsin in plasma of type 1 diabetic subjects. Biochem Biophys Res Commun. 2004;315:297–305.
   PubMed Web of Science ®Google Scholar
• Ochayon DE, Mizrahi M, Shahaf G, et al. Human alpha1-antitrypsin binds to heat-shock protein gp96 and protects from endogenous gp96-mediated injury in vivo. Front Immunol. 2013;4:320.
   PubMed Web of Science ®Google Scholar
• Guttman O, Baranovski BM, Schuster R, et al. Acute-phase protein alpha1-anti-trypsin: diverting injurious innate and adaptive immune responses from non-authentic threats. Clin Exp Immunol. 2015;179:161–72.
   PubMed Web of Science ®Google Scholar
• Bergin DA, Hurley K, McElvaney NG, et al. Alpha-1 antitrypsin: a potent anti-inflammatory and potential novel therapeutic agent. Arch Immunol Ther Exp (Warsz). 2012;60:81–97.
   PubMed Web of Science ®Google Scholar
• Kaner Z, Ochayon DE, Shahaf G, et al. Acute phase protein alpha1-antitrypsin reduces the bacterial burden in mice by selective modulation of innate cell responses. J Infect Dis. 2015;211:1489–1498.
   PubMed Web of Science ®Google Scholar
• Ehlers MR. Immune-modulating effects of alpha-1 antitrypsin. Biol Chem. 2014;395:1187–1193.
   PubMed Web of Science ®Google Scholar
• Lewis EC, Shapiro L, Bowers OJ, et al. Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice. Proc Natl Acad Sci U S A. 2005;102:12153–12158.
   PubMed Web of Science ®Google Scholar
• Lewis EC. Expanding the clinical indications for alpha(1)-antitrypsin therapy. Mol Med. 2012;18:957–70.
   PubMed Web of Science ®Google Scholar
• Cantin AM, Woods DE. Aerosolized prolastin suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection. Am J Respir Crit Care Med. 1999;160:1130–1135.
   PubMed Web of Science ®Google Scholar
• Congote LF. Serpin A1 and CD91 as host instruments against HIV-1 infection: are extracellular antiviral peptides acting as intracellular messengers? Virus Res. 2007;125:119–134.
   PubMed Web of Science ®Google Scholar
• Bristow CL, Babayeva MA, LaBrunda M, et al. alpha1Proteinase inhibitor regulates CD4+ lymphocyte levels and is rate limiting in HIV-1 disease. PLoS One. 2012;7:e31383.
   PubMed Web of Science ®Google Scholar
• Moreno JA, Ortega-Gomez A, Rubio-Navarro A, et al. High-density lipoproteins potentiate alpha1-antitrypsin therapy in elastase-induced pulmonary emphysema. Am J Respir Cell Mol Biol. 2014;51:536–549.
   PubMed Web of Science ®Google Scholar
• Subramaniyam D, Zhou H, Liang M, et al. Cholesterol rich lipid raft microdomains are gateway for acute phase protein, SERPINA1. Int J Biochem Cell Biol. 2010;42:1562–1570.
   PubMed Web of Science ®Google Scholar
• Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of HDL. J Clin Invest. 2007;117:746–756.
   PubMed Web of Science ®Google Scholar
• Talmud PJ, Martin S, Steiner G, et al. Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. Arterioscler Thromb Vasc Biol. 2003;23:644–649.
   PubMed Web of Science ®Google Scholar
• Kalis M, Kumar R, Janciauskiene S, et al. alpha 1-antitrypsin enhances insulin secretion and prevents cytokine-mediated apoptosis in pancreatic beta-cells. Islets. 2010;2:185–189.
   PubMed Web of Science ®Google Scholar
• Petrache I, Fijalkowska I, Medler TR, et al. alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis. Am J Pathol. 2006;169:1155–1166.
   PubMed Web of Science ®Google Scholar
• Gao W, Zhao J, Kim H, et al. alpha1-Antitrypsin inhibits ischemia reperfusion-induced lung injury by reducing inflammatory response and cell death. J Heart Lung Transplant. 2014;33:309–315.
   PubMed Web of Science ®Google Scholar
• Zhang B, Lu Y, Campbell-Thompson M, et al. Alpha1-antitrypsin protects beta-cells from apoptosis. Diabetes. 2007;56:1316–1323.
   PubMed Web of Science ®Google Scholar
• Nathan I, Lewis E, Khalfin B, Antinecrotic activity of alpha 1-antitrypsin. US 20110237496A1. 2009.
   Google Scholar
• Jonigk D, Al-Omari M, Maegel L, et al. Anti-inflammatory and immunomodulatory properties of alpha1-antitrypsin without inhibition of elastase. Proc Natl Acad Sci U S A. 2013;110:15007–12.
   PubMed Web of Science ®Google Scholar
• Lee S, Lee Y, Hong K, et al. Effect of recombinant alpha1-antitrypsin Fc-fused (AAT-Fc)protein on the inhibition of inflammatory cytokine production and streptozotocin-induced diabetes. Mol Med. 2013;19:65–71.
   PubMed Web of Science ®Google Scholar
• Kamada L, Phase II-III Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes. 2013. [cited 2016 Jan 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02005848
   Google Scholar
• University of Colorado, D., The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes. 2011. [cited 2016 Jan 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT01319331
   Google Scholar
• University, V.C., Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial Infarction (VCU-Alpha1RT). 2013. [cited 2016 Jan 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT01936896
   Google Scholar
• Brinkman N, et al. Methods for purification of alpha-1-antitrypsin andapolipoprotein A-1. US8436152B2. 2013.
   Google Scholar
• Brinkman N, et al. Methods for purification of alpha-1-antitrypsin and apolipoprotein A-1. US8653245B2. 2014.
   Google Scholar
• Brinkman N, Bigler D, Bolli R, et al. Methods for purification of alpha-1-antitrypsin and apolipoprotein A-1. US Patent 8,962,802. 2015.
   Google Scholar
• Dinarello C, Crapo JD, Kim S, Compositions, Methods and Uses For Alpha-1 Antitrypsin Fusion Molecules. US Patent 20,140,341,899. 2014.
   Google Scholar
• Kee SM, et al. Methods of treatment using alpha-1-antitrypsin compositions. US20150320846A1. 2015.
   Google Scholar
• Kumpalume P, Podmore A, Dalton J, Method for the purification of alpha-1-antitrypsin. US8580931B2. 2013.
   Google Scholar
• Joosten LA, Crisan TO, Azam T, et al. Alpha-1-anti-trypsin-Fc fusion protein ameliorates gouty arthritis by reducing release and extracellular processing of IL-1beta and by the induction of endogenous IL-1Ra. Ann Rheum Dis. 2015. DOI:10.1136/annrheumdis-2014-206966.
   Google Scholar
• Weir MR, Fink JC. Risk for posttransplant Diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis. 1999;34:1–13.
   PubMed Web of Science ®Google Scholar
• Drachenberg CB, Klassen DK, Weir MR, et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation. 1999;68:396–402.
   PubMed Web of Science ®Google Scholar
• Tawara I, Sun Y, Lewis EC, et al. Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proc Natl Acad Sci U S A. 2012;109:564–569.
   PubMed Web of Science ®Google Scholar
• Mizrahi M, Cal P, Rosenthal M, et al. Human alpha1-antitrypsin modifies B-lymphocyte responses during allograft transplantation. Immunology. 2013;140:362–373.
   PubMed Web of Science ®Google Scholar
• Shapiro L, Methods and compositions for treating diabetes. US8071551B2. 2008.
   Google Scholar
• Crapo JD, Marcondes AMQ, Deeg HJ, Method for ameliorating radiation exposure effects with alpha-1 antitrypsin. US8980574B2. 2015.
   Google Scholar
• Lewis EC, et al. Compositions, methods and uses for treatment of type 1 diabetes. US20120225813A1. 2012.
   Google Scholar
• Lewis EC, Dinarello CA, Shapiro L, Methods and compositions for treatment of graft rejection and promotion of graft survival. US20120045460A1. 2011.
   Google Scholar
• Lewis E, Combined therapy of alpha-1-antitrypsin and temporal t-cell depletion for preventing graft rejection. US20150010581A1. 2013.
   Google Scholar
• Quintana AG, Martin JA, Use of alpha-1-antitrypsin for the preparation of drugs for the treatment of chronic fatigue syndrome. US9205134B2. 2012.
   Google Scholar
• Shapiro L, Compositions of, and methods for, alpha-1 anti-trypsin Fc fusion molecules. US20140370036A1. 2014.
   Google Scholar
• Shapiro L, Compositions of, and methods for, Alpha-1 antitrypsin Fc fusion molecules. US8633305B2. 2014.
   Google Scholar
• Shapiro L. Methods and compositions for treating diabetes. US20120040913A1. 2012.
   Google Scholar
• Leland S, Lewis EC, Dinarello CA, Compositions and methods related to graft versus host disease and treatments thereof. US20140242096A1. 2014.
   Google Scholar
• Leland S, Lewis EC, Dinarello CA, Compositions and methods related to graft versus host disease and treatments thereof. US20140127201A1. 2014.
   Google Scholar
• Griese M, Latzin P, Kappler M, et al. alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J. 2007;29:240–250.
   PubMed Web of Science ®Google Scholar
• Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest. 2000;118:1480–1485.
   PubMed Web of Science ®Google Scholar
• Petrache I, Hajjar J, Campos M. Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency. Biologics. 2009;3:193–204.
   PubMedGoogle Scholar
• Pott GB, Beard KS, Bryan CL, et al. Alpha-1 antitrypsin reduces severity of pseudomonas pneumonia in mice and inhibits epithelial barrier disruption and pseudomonas invasion of respiratory epithelial cells. Front Public Health. 2013;1:19.
   PubMedGoogle Scholar
• Shapiro L, Serine protease inhibitors for treatment of bacterial infections. WO2008142397A1. 2005.
   Google Scholar
• Clark JE, Fai Ng W, Watson S, et al. The aetiopathogenesis of fatigue: unpredictable, complex and persistent. Br Med Bull. 2016. DOI:10.1093/bmb/ldv057.
   PubMed Web of Science ®Google Scholar
• Romano GF, Tomassi S, Russell A, et al. Fibromyalgia and chronic fatigue: the underlying biology and related theoretical issues. Adv Psychosom Med. 2015;34:61–77.
   PubMed Web of Science ®Google Scholar
• Afari N, Buchwald D. Chronic fatigue syndrome: a review. Am J Psychiatry. 2003;160:221–236.
   PubMed Web of Science ®Google Scholar
• Morris G, Berk M, Galecki P, et al. The emerging role of autoimmunity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/cfs). Mol Neurobiol. 2014;49:741–756.
   PubMed Web of Science ®Google Scholar